Breaking News

Jupiter Neurosciences has filed with the SEC for a firm commitment initial public offering of unit consisting of one share of its common stock and one warrant to purchase one share of its common stock. The warrants will expire on the two-year anniversary of the initial exercise date. The company intends to apply to list its common stock and warrants on the Nasdaq Capital Market under the symbols "JUNS" and "JUNSW" respectively. In its prospectus, Jupiter states in part: "Jupiter Neurosciences is a clinical stage research and development pharmaceutical company located in Jupiter, Florida... The company has developed a unique resveratrol platform product targeting treatment of neuro-inflammation. The product, called Jotrol, has many potential indications of use for rare diseases, which of we primarily are targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and MELAS as well as ALS which is in an early development stage. In the larger disease areas, we are primarily targeting Mild Cognitive Impairment/early Alzheimer's disease with TBI/concussions and Covid-19 in early development stages... Based on available scientific literature, we believe that Jotrol is the first and only resveratrol product in the world that delivers a therapeutically effective dose of resveratrol in the blood stream without causing gastrointestinal side effects... For the fiscal years ended December 31, 2020 and 2019, we generated no revenues from product sales and reported net losses of $1,654,699 and $3,046,719, respectively, and negative cash flow from operating activities of $254,783 and $142,952, respectively. For the six months ended June 30, 2021 and 2020, we generated no revenues from product sales and reported net losses of $1,103,876 and $702,378, respectively, and negative cash flow from operating activities of $39,799 and $121,975, respectively."